Dr. Ahmad Tarhini on Ipilimumab vs Interferon-α2b for Resected High-Risk Melanoma

Leggi l'articolo originale


Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III United States Intergroup E1609 trial, presented at ASCO 2019.

Lascia un commento